Longeveron Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.2M-50.0% YoYTTM through 31 Dec 2025
Net Income -$22.7MTTM through 31 Dec 2025
Free Cash Flow -$18.8MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 66.7% |
| Operating Margin | -1,941.7% |
| Net Margin | -1,891.7% |
Returns
-400.1%ROE
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.33x
Net Debt-$4.7Mnet cash position
Cash & Equivalents$4.7M
Quality Metrics
FCF Margin-1,566.7%
Rule of 40-1,544.3
Earnings-Beat Rate50.0%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Clinical trial revenue | $954K | -32.0% | |
| Contract manufacturing revenue | $246K | -75.4% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.